News update as of February 15, 2026. A regulatory mindful report tracks a clinical trial of noninvasive vagus nerve stimulation for chronic musculoskeletal pain and autonomic dysfunction. The study identified as NCT07409363 is sponsored by the University of Leeds and The Leeds Teaching Hospitals NHS Trust. It compares active vagus nerve stimulation with subtherapeutic stimulation, also known as sham control. The trial status is not yet recruiting. Regulators, clinicians, device makers, and patient advocates should watch for recruitment developments and any forthcoming data that could inform safety and performance assessments.
In this article
What changed in the trial landscape for noninvasive vagus nerve stimulation?
New ClinicalTrials.gov registry entries describe a device based approach to treat chronic musculoskeletal pain and autonomic dysfunction. The trial uses active stimulation against a subtherapeutic sham control to examine safety and performance in real world conditions. Sponsorship remains with University of Leeds and The Leeds Teaching Hospitals NHS Trust. The not yet recruiting status signals early stage activity rather than active enrollment at this time. This addition adds to the evolving evidence base for neuromodulation approaches in pain and autonomic disorders.
What are the study design and endpoints?
The two arms include active vagus nerve stimulation and subtherapeutic stimulation, a sham control. The device is studied for chronic musculoskeletal pain and autonomic dysfunction. The description here does not specify numeric endpoints; it reflects a regulatory style trial design that seeks to assess safety and performance until regulators and sponsors publish results.
Who is sponsoring and what is the status?
The trial is sponsored by the University of Leeds and The Leeds Teaching Hospitals NHS Trust. The entry on ClinicalTrials.gov lists the status as not yet recruiting, indicating planning or early site activity rather than ongoing enrollment. The trial uses a noninvasive vagus nerve stimulation device to address the specified conditions.
What are the regulatory implications for clinicians and device makers?
As with similar neuromodulation studies, the safety and performance data collected in this trial will inform potential future regulatory submissions. Regulators and device manufacturers can monitor the study for signals related to safety, tolerability, and device performance. Any final conclusions will rely on complete trial results once published.
- Q1. What is noninvasive vagus nerve stimulation?
Noninvasive vagus nerve stimulation is a device based approach intended to modulate autonomic function through external stimulation of the vagus nerve. The description here reflects a trial context.
- Q2. What is a sham control in this trial?
The study uses subtherapeutic stimulation as a sham control to compare against active stimulation, supporting blinded assessment.
- Q3. What is NCT07409363?
The ClinicalTrials.gov identifier refers to a not yet recruiting study sponsored by the University of Leeds and The Leeds Teaching Hospitals NHS Trust evaluating noninvasive vagus nerve stimulation for chronic musculoskeletal pain and autonomic symptoms.
Conclusion and implications
This update shows ongoing evaluation of noninvasive vagus nerve stimulation for chronic musculoskeletal pain. Stakeholders should track status on ClinicalTrials.gov for recruitment updates and look for data that may inform device safety and performance in this indication.
https://clinicaltrials.gov/study/NCT07409363?term=medical+device